文献速递核素与放射性配体治疗肿瘤 PET/CT放射性药物与辐射防护

PSMA-GCK01:一种基于发生器的99mTc/188Re前列腺特异性膜抗原诊疗一体化配体

PSMA-GCK01: A Generator-Based 99mTc/188Re Theranostic Ligand for the Prostate-Specific Membrane Antigen.
PubMed 文献 · J Nucl Med · 2023-02-09

研究以HYNIC-iPSMA为前体,用巯基乙酰三丝氨酸替换HYNIC螯合剂获得PSMA-GCK01,实现99mTc与188Re稳定标记。体外实验显示99mTc-PSMA-GCK01与99mTc-EDDA/HYNIC-iPSMA摄取特征相当;LNCaP荷瘤小鼠平面显像与器官分布显示注射后1和3小时肿瘤摄取良好、非靶器官摄取低。3例前列腺癌患者在同情用药下应用该诊疗一体化配对,99mTc-PSMA-GCK01与188Re-PSMA-GCK01分布模式相似,并与177Lu-PSMA-617比较。

要点

  • PSMA-GCK01可稳定标记99mTc与188Re两种发生器来源核素。
  • 99mTc-PSMA-GCK01与99mTc-EDDA/HYNIC-iPSMA体外摄取特征相当。
  • 3例患者中99mTc与188Re标记的PSMA-GCK01分布模式相似。

核心结论

  • PSMA-GCK01可与99mTc和188Re两种发生器来源核素稳定标记,从而以合理成本实现按需标记。
  • 临床前评估显示该PSMA靶向诊疗一体化配对具有良好特性,并已成功转化为首次人体应用。

研究设计与样本

  • 临床前研究:选择HYNIC-iPSMA为前导结构,将其HYNIC螯合剂替换为巯基乙酰三丝氨酸获得PSMA-GCK01。
  • 体外评估99mTc-PSMA-GCK01并与99mTc-EDDA/HYNIC-iPSMA比较。
  • 使用LNCaP荷瘤小鼠进行99mTc-PSMA-GCK01平面显像和188Re-PSMA-GCK01器官生物分布研究。
  • 在3例前列腺癌患者中于同情用药下应用该诊疗一体化配对进行显像与治疗。

主要发现

  • PSMA-GCK01与两种核素均实现高效放射性标记。
  • 99mTc-PSMA-GCK01与99mTc-EDDA/HYNIC-iPSMA的细胞实验显示摄取特征相当。
  • 平面显像与器官分布显示注射后1和3小时99mTc-PSMA-GCK01和188Re-PSMA-GCK01肿瘤摄取良好,非靶器官摄取低。
  • 患者中99mTc-PSMA-GCK01与188Re-PSMA-GCK01分布模式相似,并与177Lu-PSMA-617比较。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Prostate-specific membrane antigen (PSMA) theranostics have been introduced with 68Ga and 177Lu, the most used radionuclides. However, 188Re is a well-known generator-based therapeutic nuclide that completes a theranostic tandem with 99mTc and may offer an interesting alternative to the currently used radionuclides. In the present work, we aimed at the development of a PSMA-targeted 99mTc/188Re theranostic tandem. Methods: The ligand HYNIC-iPSMA was chosen as the lead structure. Its HYNIC chelator has limitations for 188Re labeling and was replaced by mercaptoacetyltriserine to obtain PSMA-GCK01, a precursor for stable 99mTc and 188Re labeling. 99mTc-PSMA-GCK01 was used for in vitro evaluation of the ligand and comparison with 99mTc-EDDA/HYNIC-iPSMA. Planar imaging using 99mTc-PSMA-GCK01 and organ biodistribution with 188Re-PSMA-GCK01 were performed using LNCaP tumor-bearing mice. Finally, the theranostic tandem was applied for imaging and therapy in 3 prostate cancer patients in compassionate care. Results: Efficient radiolabeling of PSMA-GCK01 with both radionuclides was demonstrated. Cell-based assays with 99mTc-PSMA-GCK01 versus 99mTc-EDDA/HYNIC-iPSMA revealed comparable uptake characteristics. Planar imaging and organ distribution revealed good tumor uptake of both 99mTc-PSMA-GCK01 and 188Re-PSMA-GCK01 at 1 and 3 h after injection, with low uptake in nontarget organs. In patients, similar distribution patterns were observed for 99mTc-PSMA-GCK01 and 188Re-PSMA-GCK01 and in comparison with 177Lu-PSMA-617. Conclusion: The ligand PSMA-GCK01 labels stably with 99mTc and 188Re, both generator-based radionuclides, and thus provides access to on-demand labeling at reasonable costs. Preclinical evaluation of the compounds revealed favorable characteristics of the PSMA-targeted theranostic tandem. This result was confirmed by successful translation into first-in-humans application.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Cardinale J, Giesel FL, Wensky C, et al. PSMA-GCK01: A Generator-Based 99mTc/188Re Theranostic Ligand for the Prostate-Specific Membrane Antigen. J Nucl Med. 2023. PMID: 36759199. doi:10.2967/jnumed.122.264944

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。